Results 31 to 40 of about 9,231 (199)
Urticarial vasculitis coexisting with primary myelofibrosis – a case report
Introduction . Urticarial vasculitis is a subtype of cutaneous leukocytoclastic vasculitis. The disease often accompanies systemic disorders, including hematologic malignancies, connective tissue diseases, and infectious diseases, or may be drug-induced.
Adam Reich, Radomir Reszke
core +1 more source
Understanding the link between PMN-MDSCs and CXCL8-CXCR1/2 axis in primary myelofibrosis
Emergency myelopoiesis in cancer and chronic inflammation leads to the accumulation of myeloid-derived suppressor cells (MDSCs) which localize at tumor sites or areas of chronic inflammation, serving as suppressor cells.
Rita Campanelli +12 more
doaj +1 more source
Herein, we report the first case presentation of paraneoplastic myelofibrosis associated with cancer. Paraneoplastic syndromes occur in some patients with thoracic malignancies; however, myelofibrosis is not commonly seen in non-small cell lung cancer ...
Lindsey Sloan +6 more
doaj +1 more source
Myelofibrosis is a reactive process common to many malignant and benign disorders. Primary myelofibrosis is a chronic myeloproliferative disorder of unknown aetiology that involves a multipotent haemopoietic progenitor cell and results in abnormalities ...
Jerry L. Spivak
core +1 more source
Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley +1 more source
Thrombopoietin-receptor agonists increase platelet counts by stimulating the thrombopoietin receptor. Bone marrow fibrosis has been reported in patients receiving thrombopoietin-receptor agonists.
Waleed Ghanima +6 more
doaj +1 more source
The aim of the present study was to assess the beneficial and harmful effects of ruxolitinib in patients with myelofibrosis (MF). The Cochrane databases, PubMed and Embase were searched for studies published up to October 2012. Randomised controlled trials assessing ruxolitinib versus a placebo or the best available therapy in patients with MF were ...
GU, LIAN +8 more
openaire +3 more sources
Survival of patients with primary myelofibrosis.
Patients were categorized according they were diagnosed with prefibrotic myelofibrosis, myelofibrosis-fibrotic type with early bone marrow fibrosis (grade 1) or myelofibrosis-fibrotic type with advanced bone marrow fibrosis (grade 2 or 3).
Paolo Catarsi (325689) +12 more
core +1 more source
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac +16 more
wiley +1 more source
A case of mistaken identity: When lupus masquerades as primary myelofibrosis
Introduction: Autoimmune myelofibrosis is an uncommon hematologic disease characterized by anemia, bone marrow myelofibrosis, and an autoimmune feature. Myelofibrosis is often associated with other conditions, including infections, nutritional/endocrine ...
Edy Hasrouni +8 more
doaj +1 more source

